
Topic
Orange Book
Patent/exclusivity records, therapeutic-equivalence codes, reference-listed drugs, and ANDA planning.

Pricing & Access· July 16, 2026 · 23 min read

Generics· July 15, 2026 · 29 min read
2026–2027 Generic Launch Scorecard: Which Patent Cliffs Are Worth Filing
By Ran Chen#Orange Book#Generic Entry#ANDA Approval

Pricing & Access· July 14, 2026 · 20 min read
PNH Access Landscape: C5 Blockers, Orals, and the Biosimilar Cliff
By Ran Chen#Rare Disease#Payer Policy#HCPCS Coding

Pricing & Access· July 13, 2026 · 20 min read
ATTR-CM Access Landscape: Tafamidis, Acoramidis, and Vutrisiran
By Ran Chen#Rare Disease#Payer Coverage#Payer Criteria

Pricing & Access· July 11, 2026 · 16 min read
GSK Portfolio Dossier: ViiV HIV, Nucala Runway, and Oncology Rebuild
By Ran Chen#HIV#Respiratory#Infectious Disease

Pricing & Access· July 11, 2026 · 16 min read
Sanofi Portfolio Dossier: Dupixent Growth, Lantus Cliff, and Altuviiio Pivot
By Ran Chen#Immunology#Orange Book#Purple Book

Pricing & Access· July 10, 2026 · 21 min read
AstraZeneca Portfolio Dossier: Farxiga Cliff, Enhertu Pivot, and Soliris Conversion
By Ran Chen#Orange Book#Purple Book#Medicare Part D

Pricing & Access· July 9, 2026 · 18 min read
AbbVie Portfolio Dossier: Skyrizi, Rinvoq, and 2030s Patent Cliffs
By Ran Chen#Immunology#Orange Book#Purple Book

Pricing & Access· July 8, 2026 · 22 min read
Gilead Sciences Portfolio Dossier: The Biktarvy Cliff, Yeztugo PrEP, and an Oncology Reset
By Ran Chen#HIV PrEP#Generic Entry#Drug Pricing

Pricing & Access· July 7, 2026 · 17 min read
BMS Portfolio Dossier: The Eliquis Cliff, Opdivo Lifecycle, and Cobenfy Bet
By Ran Chen#Orange Book#Purple Book#Medicare Part D